April, 9, 2024 – The “Company” today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world’s top researchers. Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC-AD1, IGC Pharma’s lead therapeutic candidate targeting agitation in Alzheimer’s disease. Recent interim results from the IGC-AD1 Phase 2 trial demonstrated a clinically and statistically significant reduction in agitation compared to placebo in patients with Alzheimer’s disease, indicating strong therapeutic potential.
As an Advisor, Dr. Arbelaez aims to utilize AI to analyze variations in disease signatures among patients with a view towards precision and personalized medicine. This will help IGC Pharma identify individuals who are most likely to respond to treatment and accelerate the delivery of treatments to patients. Dr. Arbelaez will advise the Company on the development and training of deep learning algorithms using state-of-the-art transformer architectures. The main goal is to predict the temporal progression of approximately 1,500 physiological and psychological variables for each patient enrolled in the IGC-AD1 Phase 2 clinical trial.
Pablo Arbeláez is a distinguished researcher with over 20 years of experience in Computer Vision and Artificial Intelligence. He obtained his undergraduate degree in Mathematics at Universidad de los Andes and a master’s in applied mathematics from Paris-Dauphine University. He earned a Ph.D. in Applied Mathematics with honors from Paris-Dauphine University in 2005. Between 2007 and 2014, he was a senior research scientist with the Computer Vision Group at the University of California, Berkeley. In 2014, Pablo Arbeláez became a professor in the Department of Biomedical Engineering at Universidad de los Andes. Since 2020, Arbeláez has been the director of the Center for Research and Formation in Artificial Intelligence (CinfonIA) at Universidad de los Andes, the first AI-focused academic center in Latin America, demonstrating his commitment to transformative AI solutions and empowering Latin American talent in the global AI community. He has contributed significantly to fundamental problems in Computer Vision, and his main research focus is on applications of Artificial Intelligence for Social Good.
Ram Mukunda stated, “We welcome Dr. Pablo Arbelaez to our team of Senior Advisors. His expertise in AI will aid in enhancing early detection methods for Alzheimer’s disease and subsequently aiding faster diagnoses, which is essential for effective treatment. According to the Alzheimer’s Association, up to 50 percent of people with Alzheimer’s or a similar form of dementia do not receive a formal diagnosis. By integrating AI algorithms into the screening process to analyze clinical trials and other data, and with the help of Dr. Arbelaez, the Company aims to reduce the risk of false negatives in the early diagnosis of Alzheimer’s disease.”
The addition of Dr. Pablo Arbelaez, Ph.D., will continue to support the positive interim results for IGC-AD1 in reducing agitation in Alzheimer’s disease. The interim data validate the potential of IGC-AD1 as a transformative therapeutic option with a large market opportunity in the treatment of Alzheimer’s disease.
About IGC Pharma S.A.S.
IGC Pharma SAS is at the forefront of integrating artificial intelligence (AI) into drug discovery, clinical research, and early disease detection. We are committed to revolutionizing the pharmaceutical landscape by leveraging AI-driven solutions to enhance Alzheimer’s disease (AD) research, biomarker identification, and patient diagnostics.
Our team of biomedical engineers, data scientists, and clinical researchers utilizes advanced AI models to accelerate drug development, optimize clinical trials, and improve early detection of neurodegenerative diseases. We apply cutting-edge deep learning techniques to analyze vast datasets, uncover novel therapeutic targets, and refine treatment strategies.
With a strong foundation in AI-powered analytics, IGC Pharma SAS is dedicated to pioneering the next generation of precision medicine, ensuring that breakthroughs in neuroscience and drug discovery translate into effective, accessible treatments for patients worldwide.
Join us in reshaping the future of healthcare through the power of AI.
